These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 26312563)
21. Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma. Shen ZY; Fang Y; Zhen L; Zhu XJ; Chen H; Liu H; Jiang B; Li GX; Deng HJ Cancer Genet; 2016 Apr; 209(4):143-53. PubMed ID: 26975699 [TBL] [Abstract][Full Text] [Related]
22. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855 [TBL] [Abstract][Full Text] [Related]
23. Banking on the future: biobanking for "omics" approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand. Mulvenna J; Yonglitthipagon P; Sripa B; Brindley PJ; Loukas A; Bethony JM Parasitol Int; 2012 Mar; 61(1):173-7. PubMed ID: 21855650 [TBL] [Abstract][Full Text] [Related]
24. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma. Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195 [TBL] [Abstract][Full Text] [Related]
26. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Chiang KC; Yeh TS; Wu RC; Pang JS; Cheng CT; Wang SY; Juang HH; Yeh CN Sci Rep; 2016 Oct; 6():36138. PubMed ID: 27782193 [TBL] [Abstract][Full Text] [Related]
27. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma. Yongvanit P; Pinlaor S; Loilome W J Hepatobiliary Pancreat Sci; 2014 May; 21(5):309-15. PubMed ID: 24408859 [TBL] [Abstract][Full Text] [Related]
28. A Promising Serum Autoantibody Marker, Anti-Heat Shock Protein 90α, for Cholangiocarcinoma. Boonjaraspinyo S; Juasook A; Boonmars T; Aukkanimart R; Silsirivanit A; Loilome W; Sriraj P; Wu Z; Ratanasuwan P Asian Pac J Cancer Prev; 2015; 16(14):5779-85. PubMed ID: 26320451 [TBL] [Abstract][Full Text] [Related]
29. Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture. Walter D; Herrmann E; Winkelmann R; Albert JG; Liese J; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S Histopathology; 2016 Dec; 69(6):962-970. PubMed ID: 27442966 [TBL] [Abstract][Full Text] [Related]
30. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181 [TBL] [Abstract][Full Text] [Related]
31. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073 [TBL] [Abstract][Full Text] [Related]
32. Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis. Zhou J; Shen W; He X; Qian J; Liu S; Yu G Int J Clin Exp Pathol; 2015; 8(9):9863-74. PubMed ID: 26617696 [TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Xu Y; Wang Z; Jiang X; Cui Y Biomed Pharmacother; 2017 Aug; 92():17-23. PubMed ID: 28528181 [TBL] [Abstract][Full Text] [Related]
35. Hepatic cytochrome P450 2A6 and 2E1 status in peri-tumor tissues of patients with Opisthorchis viverrini-associated cholangiocarcinoma. Yongvanit P; Phanomsri E; Namwat N; Kampan J; Tassaneeyakul W; Loilome W; Puapairoj A; Khuntikeo N Parasitol Int; 2012 Mar; 61(1):162-6. PubMed ID: 21745589 [TBL] [Abstract][Full Text] [Related]
36. Plasma phosphoproteome and differential plasma phosphoproteins with opisthorchis viverrini-related cholangiocarcinoma. Kotawong K; Thitapakorn V; Roytrakul S; Phaonakrop N; Viyanant V; Na-Bangchang K Asian Pac J Cancer Prev; 2015; 16(3):1011-8. PubMed ID: 25735322 [TBL] [Abstract][Full Text] [Related]
37. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434 [TBL] [Abstract][Full Text] [Related]
38. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell. Xiong GP; Zhang JX; Gu SP; Wu YB; Liu JF Neoplasma; 2012; 59(4):409-15. PubMed ID: 22489696 [TBL] [Abstract][Full Text] [Related]
39. Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma patients. Chamadol N; Pairojkul C; Khuntikeo N; Laopaiboon V; Loilome W; Sithithaworn P; Yongvanit P J Hepatobiliary Pancreat Sci; 2014 May; 21(5):316-22. PubMed ID: 24420706 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Lok T; Chen L; Lin F; Wang HL Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]